心玮医疗-B回购明细 | 日期 | 回购股数 （万股） | 回购最高价 （港元） | 回购最低价 （港元） | 回购金额 （万港元） | | --- | --- | --- | --- | --- | | 2026.01.09 | 6.88 | 61.100 | 57.550 | 405.68 | | 2026.01.08 | 0.55 | 59.800 | 58.750 | 32.58 | | 2026.01.07 | 3.82 | 58.750 | 56.600 | 220.01 | | 2026.01.02 | 2.72 | 54.600 | 53.400 | 146.62 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 自1月7日以来公司已连续3日进行回购，合计回购11.25万股，累计回购金额658.26万港元。 其间该股累 计上涨5.25%。 今年以来该股累计进行4次回购，合计回购13.97万股，累计回购金额804.89万港元。（数据宝） （原标题：心玮医疗-B(06609.HK)1月9日回购6.88万股，耗资405.68万港元） 证券时报•数据宝统计，心玮医疗-B在港交所公告显示 ...

相关事件 格隆汇1月9日丨心玮医疗-B(06609.HK)发布公告，2026年1月9日耗资405.68万港元回购6.88万股，回购 价格每股57.55-61.1港元。 心玮医疗-B(06609.HK)1月9日耗资405.68万港元回购6.88万股 脑机接口风口下的价值重估，心玮医疗- B(6609.HK)的技术卡位与资本进阶 ...

心玮医疗-B(06609)发布公告，该公司于2026年1月9日斥资405.68万港元回购6.88万股股份，每股回购价 格为57.55-61.1港元。 ...

智通财经APP讯，心玮医疗-B(06609)发布公告，该公司于2026年1月9日斥资405.68万港元回购6.88万股 股份，每股回购价格为57.55-61.1港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海心瑋醫療科技股份有限公司 (於中華人民共和國註冊成立的有限責任公司) 呈交日期： 2026年1月9日 FF305 FF305 確認 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06609 | 說明 | H股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份 ...

Summary of New Wei Medical Conference Call Company Overview - New Wei Medical focuses on interventional brain-machine interface technology, utilizing a minimally invasive approach through the jugular vein to access brain vessels for signal collection, differentiating itself from invasive technologies like those developed by Musk's company [2][5] Key Points and Arguments - **Product Development Timeline**: New Wei Medical plans to complete type testing and animal experiments by mid-2026, initiate clinical enrollment in the second half of 2026, and expects to finish all patient enrollment and submit for regulatory approval by 2028 [2][3][4] - **Independent Subsidiary**: The company has established an independent subsidiary named "Wei Brain Technology" to focus on the development of interventional brain-machine interfaces and related investment collaborations, with plans to expand the team to 20 members [2][9] - **Technical Specifications**: The interventional brain-machine interface device uses a nickel-titanium alloy stent with electrode configurations of 4 or 16 channels, with signal processing chips placed subcutaneously beneath the clavicle [2][8] - **Animal Testing Results**: Animal experiments have shown stable signal strength, with a small-tailed sheep experiment maintaining 97%-98% signal strength after 18 months, validating the feasibility of the technology [2][11] Competitive Landscape - **Comparison with Musk's Technology**: New Wei Medical's approach avoids the need for craniotomy, which is required by Musk's invasive technology. This results in lower surgical risks and higher patient acceptance. The company claims its method ensures stable signal transmission due to the encapsulation of the electrode stent by the vessel wall, preventing displacement issues [5][10] Clinical Trial Plans - **First Patient Enrollment**: The company plans to conduct its first clinical trial in 2026, targeting 30-50 patients primarily for limb rehabilitation indications, with a follow-up period of approximately six months [4][10] - **Regulatory Recognition**: New Wei Medical is the only approved project for interventional technology routes in a national initiative co-hosted by the Ministry of Industry and Information Technology and the National Medical Products Administration, indicating recognition of its innovative technology [4][6] Challenges and Future Directions - **Technical Limitations**: The interventional approach may face challenges in accessing smaller, more distal blood vessels, necessitating the design of smaller electrode stents for broader brain area applications [11][12] - **Future Applications**: The company aims to extend its technology from motor function areas to visual and auditory functions, as well as explore emotional management and other research directions [11][12] Additional Insights - **Market Potential**: With 2,500 hospitals in China capable of performing the minimally invasive procedure, New Wei Medical is positioned to leverage a broad market for its technology [5] - **Investment and Collaboration**: The subsidiary aims to attract external partnerships and capital to enhance its operational capabilities and cover more consumer-level application scenarios [9]

2026年开年，一则脑机接口领域的动态迅速刷屏海内外市场。 埃隆·马斯克通过社交媒体表态，其旗下"神经连接"公司将在2026年启动脑机接口设备大规模生产，同 时推进"更加精简且近乎完全自动化的外科手术流程"。这一消息在瞬间点燃资本市场对脑机接口赛道热 情的同时，更清晰揭示出该领域正从临床试验阶段加速迈向商业化落地的核心趋势。 与此同时，国内脑机接口产业同步迎来政策与市场的双重利好。全国首个脑机接口医疗服务价格正式落 地，侵入式置入费纳入医保的讨论也逐步推进，直接打破了制约医疗场景商业化的核心瓶颈。 在这场全球产业竞赛中，心玮医疗的全资子公司玮脑智联，于近日正式落户上海脑机接口未来产业集聚 区，专注于脑机接口技术的研发与临床转化，推动该技术从基础研究向临床治疗应用实现关键性跨越。 这一布局不仅标志着心玮医疗在脑机接口赛道迈入实质化落地阶段，更凸显出这家神经介入头部企业， 正凭借前瞻性的介入式脑机接口布局，站在行业红利与自身发展的双重拐点。市场对其内在价值的重 估，亦已随着2025年股价回暖、业绩盈利等信号逐步启动。 介入式路线的技术突围，绑定脑机接口红利 从高值医疗的价值逻辑而言，介入式脑机接口的核心优势集中在 ...

智通财经APP讯，心玮医疗-B(06609)发布公告，于2026年1月8日，该公司斥资32.58万港元回购5500 股。 ...

心玮医疗-B(06609)发布公告，于2026年1月8日，该公司斥资32.58万港元回购5500股。 ...

格隆汇1月8日丨心玮医疗-B(06609.HK)发布公告，2026年1月8日耗资32.58万港元回购5500股，回购价 格每股58.75-59.8港元。 ...